Abstract:Abstract Bladder cancer is one of the most common malignant tumors in the urinary system. According to NIH statistics, the 5-year survival rate of bladder cancer patients has not improved since the last three decades. Tumor immunotherapy, such as PD-L1, CAR-T, and TCR-T, brings dawn to these patients. However, there are numerous factors affecting the clinical applications and trials, such as genetic variation, drug resistance, off-target, and the low specificity of recognition and intervention of bladder cancer. We aimed to identify new targets for the specific recognition and intervention of bladder cancer and introduce single target or target combination into immune cells to develop new technologies and products for early diagnosis and clinical treatment of bladder cancer. By using large-scale sequencing technology, our team identified 21 new genes, including UTX, MLL-MLL3, and CHD6, which were highly mutated in the tumorigenesis of bladder cancer, as well as the highest-ever-found mutated gene TERT. Based on CRISPR-Cas9 system, we constructed the “AND” gate genetic circuits for bladder cancer, which integrated intracellular information from two promoters as inputs and activated the output signals only when both inputs were activated simultaneously. Furthermore, some tumor-suppressor genes can be designed as output to achieve specific inhibition or killing of bladder cancer cells. The “Artificial Nucleic Acid Aptamer” tool was used to engineer the CRISPR-Cas9 system under the control of specific signaling molecules to complete the quantitative regulation of downstream gene transcription, achieving the effect of connecting two originally unrelated signaling pathways. By combining multiple signal conductors, the oncogenic signaling could activate the downstream tumor suppressor pathway, initiating cell apoptosis and specific killing of tumor cells. Therefore, this modified system could provide insight into precision medicine in cancer treatment. The design of a series of synthetic RNA components into signal connectors could interconnect two different signals at the translation level to inhibit or enhance the expression of target genes. It could also connect the internal and external signals, reshape the gene regulation network, and redirect the oncogenic signaling to the cell apoptosis. Based on these results, our team developed CAR-T and TCR-T engineered cells for the clinical trial of bladder cancer. The effective rate of CAR-T therapy on solid and nonsolid tumors reached 60% and 87.5%, respectively. The effective rate of TCR-T therapy for NY-ESO-1 positive bladder cancer patients reached 50%, of which 2 cases were completely alleviated. In summary, our team completed a full-chain study from original discoveries to clinical applications, significantly improving the specific recognition and intervention of bladder cancer and making an important contribution to increasing 5-year survival rate and quality of life of bladder cancer patients. Note: This abstract was not presented at the conference. Citation Format: Zhiming Cai. Study on screening of new targets, specific recognition, and intervention of bladder cancer [abstract]. In: Proceedings of the AACR Special Conference on Bladder Cancer: Transforming the Field; 2019 May 18-21; Denver, CO. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(15_Suppl):Abstract nr B04.

Abstract 3161: Novel gene signature for predicting aggressive type of bladder cancer and the associated therapeutic strategies

Single-cell Sequencing Data Reveals Aggressive CD68-type Macrophages and Prognostic Models in Bladder Cancer.

A cancer-associated fibroblast subtypes-based signature enables the evaluation of immunotherapy response and prognosis in bladder cancer.

Clinical and RNA Expression Integrated Signature for Urothelial Bladder Cancer Prognosis.

Abstract 6402: Treatment resistance and survival prediction using a machine learning gene expression signature in pancreatic adenocarcinoma

Abstract 7040: Mutations in cytoskeleton genes SPTAN1/SPTBN1 serve as novel predictive markers for immunotherapy against bladder cancer

Abstract 7648: COL6A1 expression as a potential prognostic biomarker for risk stratification of T1HG bladder cancer: Unveiling the aggressive nature of a distinct non-muscle invasive subtype

Abstract 6405: Identification of molecular targets in bladder cancer variants using single-cell analysis

A novel gene signature combination improves the prediction of overall survival in urinary bladder cancer

Identification of Signature Genes Associated With Invasiveness and the Construction of a Prognostic Model That Predicts the Overall Survival of Bladder Cancer

Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer

Abstract 5028: Detection of non-small cell lung and bladder cancer signatures in peripheral blood using a novel antibody-free chromatin capture assay

Abstract B04: Study on Screening of New Targets, Specific Recognition, and Intervention of Bladder Cancer

Abstract 5093: A predictive biomarker classififier in NSCLC treated with immunotherapy

An Individualized Prognostic Signature for Clinically Predicting the Survival of Patients With Bladder Cancer

Unveiling Anoikis‐related genes: A breakthrough in the prognosis of bladder cancer

Abstract B05: Basic Research and Translational Medicine of Bladder Cancer in China

Abstract 894: Genetic Variations in the Angiogenesis Pathway Modulate Clinical Outcomes of Bladder Cancer

Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer

Abstract 6430: Gene expression signature quantifies the cellular contribution of the tumor vs. the microenvironment in determining colorectal cancer prognosis and therapeutic outcome

Abstract 7620: Immuno-transcriptomic profiling of blood and tumor tissue identifies gene signatures associated with immunotherapy response in metastatic bladder cancer